+ Translate

Photodynamic therapy in the management of resistant lower urinary tract carcinoma

, : Photodynamic therapy in the management of resistant lower urinary tract carcinoma. Cancer 60(12): 3113-3119

Twenty-three patients with resistant transitional cell carcinoma (TCC) of the bladder and posterior urethra had photodynamic therapy (PDT). Seventy-two hours after an intravenous injection with 2 mg/kg of the photosensitizer dihematoporphyrin ether (DHE) (Photofrin II, Photomedica, Raritan, NJ), each patient received cystoscopic light treatment. The light dose to the whole bladder using the bulb diffuser ranged from 5 to 60 J/cm2; power density ranged from 9 to 22 mW/cm2. The focal light dose ranged from 100 to 200 J/cm2 at a power density from 100 to 200 mW/cm2. To treat the urethra, a diffuser fiber was used to deliver 200 to 400 J/linear cm at a power of 110 to 300 mW/cm. In the 19 of 23 patients who were treated for resistant superficial TCC, 83.3% of the tumors had responded at the initial follow-up evaluation. Seven patients had a complete response and 10 had a partial response. Three of 19 patients who received inadequate light treatment failed to respond. Control of intractable gross hematuria was the only benefit for patients with locally invasive disease (.gtoreq. T2). Irritating lower urinary tract symptoms that varied in severity and duration occurred in all patients. Four patients experienced bladder shrinkage, which did not resolve. Although the light and drug doses remain to be determined, a whole bladder light dose of 15 to 20 J/cm2 with a drug dose of 2 mg/kg seems to be effective enough without producing permanent adverse effects in the bladder.

Accession: 006110657

PMID: 3677034

DOI: 10.1002/1097-0142(19871215)60:12<3113::aid-cncr2820601242>;2-2

Download PDF Full Text: Photodynamic therapy in the management of resistant lower urinary tract carcinoma

Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:

Related references

Shuber S., 1986: Photodynamic therapy for severe dysplasia and carcinoma in situ of the lower female genital tract. Lasers In Surgery & Medicine: 208

Ahmad, S.; Aboumarzouk, O.; Somani, B.; Nabi, G.; Kata, S.Grzegorz., 2013: Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit. The idea of using photosensitizing agents to enhance visualization of cancer tissue dates back to 19. 5-Aminolevulinic acid (5-ALA) was first suggested for photodynamic diagnosis (PDD) of transitional cell cancer (TCC) of the bladder in 1992. Sinc...

Audenet, Fçois.; Traxer, O.; Yates, D.R.; Cussenot, O.; Rouprêt, M., 2012: Potential role of photodynamic techniques combined with new generation flexible ureterorenoscopes and molecular markers for the management of urothelial carcinoma of the upper urinary tract. •  To discuss how the development of new generation flexible ureterorenoscopes in combination with photodynamic diagnosis (PDD) improves the assessment of urothelial cell carcinoma of the upper urinary tract (UUT-UCC). •  Ultimately, this...

Seisen, T.; Rouprêt, M., 2012: Diagnosis and therapy of upper and lower urinary tract urothelial carcinoma. Progres en Urologie 22(2 Suppl 1): H7-H9

Wein, A.J., 1987: Lower urinary tract function and pharmacologic management of lower urinary tract dysfunction. Because of renewed interest in the neuropharmacology and neurophysiology of the urinary bladder and its outlet, drug therapy can now help manage many types of voiding dysfunction. This article summarizes the scientific foundations on which this ty...

Casey, R.G.; Catto, J.W.F.; Cheng, L.; Cookson, M.S.; Herr, H.; Shariat, S.; Witjes, J.Alfred.; Black, P.C., 2016: Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic review. Urothelial carcinoma in situ (CIS) has a high propensity for progression. It is usually reported within the heterogeneous context of non-muscle-invasive bladder cancer (NMIBC) but warrants special consideration. To review the contemporary literatu...

Altaf Mangera; Christopher, 2012: Botulinum toxin therapy for the management of lower urinary tract symptoms – has this come of age?. Intravesical botulinum toxin A (BTX-A) is used extensively in the management of patients with lower urinary tract symptoms. The most common use in urology is in patients with neurogenic and idiopathic detrusor overactivity, with a recent licence b...

Patel, A.K.; Chapple, C.R., 2006: Botulinum toxin injection therapy in the management of lower urinary tract dysfunction. We have great pleasure in introducing this supplement containing a collection of articles reviewing the contemporary clinical management of functional disorders of the lower urinary tract (LUT) with particular emphasis on the potential role of bot...

Ozdemir, I.; Bozkurt, O.; Demir, O.; Aslan, G.; Esen, A.A., 2009: Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms. To compare the efficacy and safety of a combination therapy, doxazosin plus tenoxicam, and doxazosin alone for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH), as various combination therapies increase the efficacy...

Roehrborn, C.G., 2008: Clinical management of lower urinary tract symptoms with combined medical therapy. Bju International 102 Suppl 2: 13-17